Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis
Open Access
- 28 September 2023
- journal article
- research article
- Published by Springer Nature in Molecular Medicine
- Vol. 29 (1) , 1-17
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of type 2 diabetes mellitus (T2DM). The pathogenesis of NAFLD involves multiple biological changes, including insulin resistance, oxidative stress, inflammation, as well as genetic and environmental factors. Liraglutide has been used to control blood sugar. But the impact of liraglutide on T2DM-associated NAFLD remains unclear. In this study, we investigated the impact and potential molecular mechanisms of inhibiting ferroptosis for liraglutide improves T2DM-associated NAFLD. Methods: Mice were fed on high-fat-diet and injected with streptozotocin to mimic T2DM-associated NAFLD and gene expression in liver was analysed by RNA-seq. The fast blood glucose was measured during the period of liraglutide and ferrostatin-1 administration. Hematoxylin and eosin staining was used to evaluate the pathological changes in the liver. The occurrence of hepatic ferroptosis was measured by lipid peroxidation in vivo. The mechanism of liraglutide inhibition ferroptosis was investigated by in vitro cell culture. Results: Liraglutide not only improved glucose metabolism, but also ameliorated tissue damage in the livers. Transcriptomic analysis indicated that liraglutide regulates lipid metabolism related signaling including AMPK and ACC. Furthermore, ferroptosis inhibitor rather than other cell death inhibitors rescued liver cell viability in the presence of high glucose. Mechanistically, liraglutide-induced activation of AMPK phosphorylated ACC, while AMPK inhibitor compound C blocked the liraglutide-mediated suppression of ferroptosis. Moreover, ferroptosis inhibitor restored liver function in T2DM mice in vivo. Conclusions: These findings indicate that liraglutide ameliorates the T2DM-associated NAFLD, which possibly through the activation of AMPK/ACC pathway and inhibition of ferroptosis.Keywords
Funding Information
- National Natural Science Foundation of China (81471031, 82103272)
- Basic & Clinical Sciences Integration Innovation Project of Xi’an Jiaotong University (YXJLRH2022018)
- Fundamental Research Funds for the Central Universities (xzd012022099)
- Natural Science Basic Research Program of Shaanxi (2023-JC-ZD-47, 2023-JC-QN-0921)
- Research Project of Shaanxi Administration of Traditional Chinese Medicine (SZY-KJCYC-2023-008)
This publication has 64 references indexed in Scilit:
- Type 2 diabetes mellitusNature Reviews Disease Primers, 2015
- Molecular pathways in non-alcoholic fatty liver diseaseClinical and Experimental Gastroenterology, 2014
- Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metforminNature Medicine, 2013
- Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy miceInternational Journal of Molecular Medicine, 2013
- GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− MiceEndocrinology, 2013
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase–Dependent Regulation of the Orphan Nuclear Receptor SHPDiabetes, 2008
- The Physiology of Glucagon-like Peptide 1Physiological Reviews, 2007
- Hepatic De Novo Lipogenesis Is Present in Liver-Specific ACC1-Deficient MiceMolecular and Cellular Biology, 2007
- Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspectsJournal of Hepatology, 2001